# A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

Source: https://onco.cc/trials/nct02632305/  
OnCo record `nct02632305` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, active and no longer recruiting.

## Summary

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer is a phase 2 interventional study registered as NCT02632305 by AHS Cancer Control Alberta, with a registry enrolment figure of 45 participants, started 2016-07-13 and due to reach its primary completion in 2026-12. Interventions recorded: nab-paclitaxel in combination with gemcitabine + cisplatin. Conditions listed: Unresectable Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "1. Histologically documented locally advanced or metastatic BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) not previously treated with palliative systemic therapy or rad". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: AX-CSARC
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT02632305
- Phase: 2
- Setting: A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer
- Sponsor: AHS Cancer Control Alberta
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT02632305: https://clinicaltrials.gov/study/NCT02632305

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct02632305.json